China-based Jacobio Pharma (HKG: 1167) has presented clinical data for its KRAS G12C inhibitor glecirasib in combination with its pipeline SHP2 inhibitor JAB-3312 at the European Society for Medical Oncology (ESMO) Congress 2023. The data comes from a Phase I/II study that enrolled 144 patients with KRAS G12C mutated cancers, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic cancer.
Clinical Trial Results
In the study, the glecirasib/JAB-3312 combination regimen demonstrated an objective response rate (ORR) of 65.5% and a disease control rate (DCR) of 100% among advanced NSCLC patients in the first-line setting. Notably, in the dose groups of 800mg glecirasib and 2mg JAB-3312, the ORR reached 86.7%, with the DCR remaining at 100%. These results underscore the safety and efficacy of the combination therapy.
Development and Clinical Trials
Glecirasib, developed in-house by Jacobio, is currently the subject of several Phase I/II clinical trials in China, the US, and Europe for patients with advanced solid tumors harboring the KRAS G12C mutation. These trials include a pivotal clinical trial in NSCLC in China, a monotherapy study for STK11 co-mutated NSCLC in the front-line setting, and combination therapy trials with JAB-3312, an anti-PD-1 antibody, and cetuximab. JAB-3312 is also undergoing multiple clinical trials across China, the US, and Europe.-Fineline Info & Tech
